Head And Neck Cancer - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 1466
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H793E1D896CEN
Leaflet:

Download PDF Leaflet

Head And Neck Cancer - Pipeline Review, H2 2017
Head And Neck Cancer - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer - Pipeline Review, H2 2017, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape.

Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 18, 96, 115, 5, 85, 18 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 7, 16 and 3 molecules, respectively.

Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Head And Neck Cancer - Overview
Head And Neck Cancer - Therapeutics Development
Head And Neck Cancer - Therapeutics Assessment
Head And Neck Cancer - Companies Involved in Therapeutics Development
Head And Neck Cancer - Drug Profiles
Head And Neck Cancer - Dormant Projects 1402
Head And Neck Cancer - Discontinued Products 1413
Head And Neck Cancer - Product Development Milestones 1415
Appendix 1428

LIST OF TABLES

Number of Products under Development for Head And Neck Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.11), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.12), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Products under Development by Companies, H2 2017 (Contd.11), H2 2017
Products under Development by Companies, H2 2017 (Contd.12), H2 2017
Products under Development by Companies, H2 2017 (Contd.13), H2 2017
Products under Development by Companies, H2 2017 (Contd.14), H2 2017
Products under Development by Companies, H2 2017 (Contd.15), H2 2017
Products under Development by Companies, H2 2017 (Contd.16), H2 2017
Products under Development by Companies, H2 2017 (Contd.17), H2 2017
Products under Development by Companies, H2 2017 (Contd.18), H2 2017
Products under Development by Companies, H2 2017 (Contd.19), H2 2017
Products under Development by Companies, H2 2017 (Contd.20), H2 2017
Products under Development by Companies, H2 2017 (Contd.21), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.7), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.8), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.7), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.8), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Number of Products by Stage and Molecule Type, H2 2017 (Contd.1), H2 2017
Head And Neck Cancer - Pipeline by 3SBio Inc, H2 2017
Head And Neck Cancer - Pipeline by 4SC AG, H2 2017
Head And Neck Cancer - Pipeline by AbbVie Inc, H2 2017
Head And Neck Cancer - Pipeline by Abion Inc, H2 2017
Head And Neck Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2017
Head And Neck Cancer - Pipeline by Aduro BioTech Inc, H2 2017
Head And Neck Cancer - Pipeline by Advaxis Inc, H2 2017
Head And Neck Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
Head And Neck Cancer - Pipeline by Affimed GmbH, H2 2017
Head And Neck Cancer - Pipeline by Altor BioScience Corp, H2 2017
Head And Neck Cancer - Pipeline by Ambrx Inc, H2 2017
Head And Neck Cancer - Pipeline by amcure GmbH, H2 2017
Head And Neck Cancer - Pipeline by Amgen Inc, H2 2017
Head And Neck Cancer - Pipeline by arGEN-X BV, H2 2017
Head And Neck Cancer - Pipeline by ArQule Inc, H2 2017
Head And Neck Cancer - Pipeline by Array BioPharma Inc, H2 2017
Head And Neck Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017
Head And Neck Cancer - Pipeline by Aspyrian Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by Astellas Pharma Inc, H2 2017
Head And Neck Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017
Head And Neck Cancer - Pipeline by AstraZeneca Plc, H2 2017
Head And Neck Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Head And Neck Cancer - Pipeline by Bayer AG, H2 2017
Head And Neck Cancer - Pipeline by BeiGene Ltd, H2 2017
Head And Neck Cancer - Pipeline by Benitec Biopharma Ltd, H2 2017
Head And Neck Cancer - Pipeline by Bexion Pharmaceuticals LLC, H2 2017
Head And Neck Cancer - Pipeline by BioDiem Ltd, H2 2017
Head And Neck Cancer - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2017
Head And Neck Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2017
Head And Neck Cancer - Pipeline by Bionovis SA, H2 2017
Head And Neck Cancer - Pipeline by BioNTech AG, H2 2017
Head And Neck Cancer - Pipeline by Biotest AG, H2 2017
Head And Neck Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2017
Head And Neck Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Head And Neck Cancer - Pipeline by Boston Biomedical Inc, H2 2017
Head And Neck Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
Head And Neck Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017
Head And Neck Cancer - Pipeline by CEL-SCI Corp, H2 2017
Head And Neck Cancer - Pipeline by Celgene Corp, H2 2017
Head And Neck Cancer - Pipeline by Cell Medica Ltd, H2 2017
Head And Neck Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by Cellectar Biosciences Inc, H2 2017
Head And Neck Cancer - Pipeline by Celprogen Inc, H2 2017
Head And Neck Cancer - Pipeline by Centrose LLC, H2 2017
Head And Neck Cancer - Pipeline by Checkpoint Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2017
Head And Neck Cancer - Pipeline by Cristal Therapeutics BV, H2 2017
Head And Neck Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2017
Head And Neck Cancer - Pipeline by Curevac AG, H2 2017
Head And Neck Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017
Head And Neck Cancer - Pipeline by CytImmune Sciences Inc, H2 2017
Head And Neck Cancer - Pipeline by CytomX Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Head And Neck Cancer - Pipeline by Denceptor Therapeutics Ltd, H2 2017
Head And Neck Cancer - Pipeline by DNJ Pharma Inc, H2 2017
Head And Neck Cancer - Pipeline by Dynavax Technologies Corp, H2 2017
Head And Neck Cancer - Pipeline by Eisai Co Ltd, H2 2017
Head And Neck Cancer - Pipeline by Eleven Biotherapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by Eli Lilly and Co, H2 2017
Head And Neck Cancer - Pipeline by Enzene Biosciences Ltd, H2 2017
Head And Neck Cancer - Pipeline by Etubics Corp, H2 2017
Head And Neck Cancer - Pipeline by Eureka Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Head And Neck Cancer - Pipeline by Forty Seven Inc, H2 2017
Head And Neck Cancer - Pipeline by Fujifilm Corp, H2 2017
Head And Neck Cancer - Pipeline by G&E Herbal Biotechnology Co Ltd, H2 2017
Head And Neck Cancer - Pipeline by Galectin Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by Genelux Corp, H2 2017
Head And Neck Cancer - Pipeline by Genentech Inc, H2 2017
Head And Neck Cancer - Pipeline by GeneSegues Inc, H2 2017
Head And Neck Cancer - Pipeline by Genexine Inc, H2 2017
Head And Neck Cancer - Pipeline by Genmab A/S, H2 2017
Head And Neck Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017
Head And Neck Cancer - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017
Head And Neck Cancer - Pipeline by Gliknik Inc, H2 2017
Head And Neck Cancer - Pipeline by Glycotope GmbH, H2 2017
Head And Neck Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Head And Neck Cancer - Pipeline by Hookipa Biotech AG, H2 2017
Head And Neck Cancer - Pipeline by Horizon Pharma Plc, H2 2017
Head And Neck Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2017
Head And Neck Cancer - Pipeline by Ignyta Inc, H2 2017
Head And Neck Cancer - Pipeline by Immatics Biotechnologies GmbH, H2 2017
Head And Neck Cancer - Pipeline by Immunocore Ltd, H2 2017
Head And Neck Cancer - Pipeline by Immunomedics Inc, H2 2017
Head And Neck Cancer - Pipeline by Immunovaccine Inc, H2 2017
Head And Neck Cancer - Pipeline by Immunovative Therapies Ltd, H2 2017
Head And Neck Cancer - Pipeline by Incyte Corp, H2 2017
Head And Neck Cancer - Pipeline by Infinity Pharmaceuticals Inc, H2 2017
Head And Neck Cancer - Pipeline by Innate Pharma SA, H2 2017
Head And Neck Cancer - Pipeline by Innovation Pharmaceuticals Inc, H2 2017
Head And Neck Cancer - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Head And Neck Cancer - Pipeline by InteRNA Technologies BV, H2 2017
Head And Neck Cancer - Pipeline by Iovance Biotherapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by IRX Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2017
Head And Neck Cancer - Pipeline by ISU ABXIS Co Ltd, H2 2017
Head And Neck Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
Head And Neck Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017
Head And Neck Cancer - Pipeline by Johnson & Johnson, H2 2017
Head And Neck Cancer - Pipeline by Jounce Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by Juno Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by Kite Pharma Inc, H2 2017
Head And Neck Cancer - Pipeline by Kura Oncology Inc, H2 2017
Head And Neck Cancer - Pipeline by Laboratoires Pierre Fabre SA, H2 2017
Head And Neck Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, H2 2017
Head And Neck Cancer - Pipeline by Loxo Oncology Inc, H2 2017
Head And Neck Cancer - Pipeline by Lytix Biopharma AS, H2 2017
Head And Neck Cancer - Pipeline by Mabion SA, H2 2017
Head And Neck Cancer - Pipeline by MacroGenics Inc, H2 2017
Head And Neck Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017
Head And Neck Cancer - Pipeline by Marsala Biotech Inc, H2 2017
Head And Neck Cancer - Pipeline by Mateon Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by MaxiVAX SA, H2 2017
Head And Neck Cancer - Pipeline by Meabco A/S, H2 2017
Head And Neck Cancer - Pipeline by MedImmune LLC, H2 2017
Head And Neck Cancer - Pipeline by Merck & Co Inc, H2 2017
Head And Neck Cancer - Pipeline by Merck KGaA, H2 2017
Head And Neck Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017
Head And Neck Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Head And Neck Cancer - Pipeline by Mirati Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by Moderna Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by Molecular Templates Inc, H2 2017
Head And Neck Cancer - Pipeline by Moleculin Biotech Inc, H2 2017
Head And Neck Cancer - Pipeline by NanoCarrier Co Ltd, H2 2017
Head And Neck Cancer - Pipeline by NantKwest Inc, H2 2017
Head And Neck Cancer - Pipeline by Natco Pharma Ltd, H2 2017
Head And Neck Cancer - Pipeline by NeoImmuneTech Inc, H2 2017
Head And Neck Cancer - Pipeline by Neonc Technologies Inc, H2 2017
Head And Neck Cancer - Pipeline by Neumedicines Inc, H2 2017
Head And Neck Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by Novartis AG, H2 2017
Head And Neck Cancer - Pipeline by Noxopharm Ltd, H2 2017
Head And Neck Cancer - Pipeline by Oncobiologics Inc, H2 2017
Head And Neck Cancer - Pipeline by Oncolys BioPharma Inc, H2 2017
Head And Neck Cancer - Pipeline by Onconova Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by OncoSec Medical Inc, H2 2017
Head And Neck Cancer - Pipeline by Oncovir Inc, H2 2017
Head And Neck Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Head And Neck Cancer - Pipeline by Oryx GmbH & Co KG, H2 2017
Head And Neck Cancer - Pipeline by Otsuka Holdings Co Ltd, H2 2017
Head And Neck Cancer - Pipeline by PDS Biotechnology Corp, H2 2017
Head And Neck Cancer - Pipeline by Peregrine Pharmaceuticals Inc, H2 2017
Head And Neck Cancer - Pipeline by Pfizer Inc, H2 2017
Head And Neck Cancer - Pipeline by Pharma Mar SA, H2 2017
Head And Neck Cancer - Pipeline by Plexxikon Inc, H2 2017
Head And Neck Cancer - Pipeline by PNP Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by Profectus BioSciences Inc, H2 2017
Head And Neck Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017
Head And Neck Cancer - Pipeline by PsiOxus Therapeutics Ltd, H2 2017
Head And Neck Cancer - Pipeline by R Pharm, H2 2017
Head And Neck Cancer - Pipeline by Redx Pharma Plc, H2 2017
Head And Neck Cancer - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
Head And Neck Cancer - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017
Head And Neck Cancer - Pipeline by Sareum Holdings Plc, H2 2017
Head And Neck Cancer - Pipeline by Selecta Biosciences Inc, H2 2017
Head And Neck Cancer - Pipeline by Shionogi & Co Ltd, H2 2017
Head And Neck Cancer - Pipeline by Sierra Oncology Inc, H2 2017
Head And Neck Cancer - Pipeline by Sillajen Biotherapeutics, H2 2017
Head And Neck Cancer - Pipeline by Sinil Pharmaceutical Co Ltd, H2 2017
Head And Neck Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by Sound Pharmaceuticals Inc, H2 2017
Head And Neck Cancer - Pipeline by Spherium Biomed SL, H2 2017
Head And Neck Cancer - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
Head And Neck Cancer - Pipeline by SuviCa Inc, H2 2017
Head And Neck Cancer - Pipeline by SynCore Biotechnology Co Ltd, H2 2017
Head And Neck Cancer - Pipeline by Systimmune Inc, H2 2017
Head And Neck Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2017
Head And Neck Cancer - Pipeline by Takara Bio Inc, H2 2017
Head And Neck Cancer - Pipeline by Takis Srl, H2 2017
Head And Neck Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2017
Head And Neck Cancer - Pipeline by Theralase Technologies Inc, H2 2017
Head And Neck Cancer - Pipeline by Theravectys SA, H2 2017
Head And Neck Cancer - Pipeline by Tolero Pharmaceuticals Inc, H2 2017
Head And Neck Cancer - Pipeline by Tosk Inc, H2 2017
Head And Neck Cancer - Pipeline by Transgene SA, H2 2017
Head And Neck Cancer - Pipeline by UbiVac LLC, H2 2017
Head And Neck Cancer - Pipeline by Vaccibody AS, H2 2017
Head And Neck Cancer - Pipeline by VasGene Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by Vault Pharma Inc, H2 2017
Head And Neck Cancer - Pipeline by Vaxeal Holding SA, H2 2017
Head And Neck Cancer - Pipeline by Vectorite Biomedica Inc, H2 2017
Head And Neck Cancer - Pipeline by Viracta Therapeutics Inc, H2 2017
Head And Neck Cancer - Pipeline by Vyriad Inc, H2 2017
Head And Neck Cancer - Dormant Projects, H2 2017
Head And Neck Cancer - Dormant Projects, H2 2017 (Contd.1), H2 2017
Head And Neck Cancer - Dormant Projects, H2 2017 (Contd.2), H2 2017
Head And Neck Cancer - Dormant Projects, H2 2017 (Contd.3), H2 2017
Head And Neck Cancer - Dormant Projects, H2 2017 (Contd.4), H2 2017
Head And Neck Cancer - Dormant Projects, H2 2017 (Contd.5), H2 2017
Head And Neck Cancer - Dormant Projects, H2 2017 (Contd.6), H2 2017
Head And Neck Cancer - Dormant Projects, H2 2017 (Contd.7), H2 2017
Head And Neck Cancer - Dormant Projects, H2 2017 (Contd.8), H2 2017
Head And Neck Cancer - Dormant Projects, H2 2017 (Contd.9), H2 2017
Head And Neck Cancer - Dormant Projects, H2 2017 (Contd.10), H2 2017
Head And Neck Cancer - Discontinued Products, H2 2017
Head And Neck Cancer - Discontinued Products, H2 2017 (Contd.1), H2 2017

LIST OF FIGURES

Number of Products under Development for Head And Neck Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

3SBio Inc
4SC AG
AbbVie Inc
Abion Inc
Adaptimmune Therapeutics Plc
Aduro BioTech Inc
Advaxis Inc
Advenchen Laboratories LLC
Affimed GmbH
Altor BioScience Corp
Ambrx Inc
amcure GmbH
Amgen Inc
arGEN-X BV
ArQule Inc
Array BioPharma Inc
Ascentage Pharma Group Corp Ltd
Aspyrian Therapeutics Inc
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
AVEO Pharmaceuticals Inc
Bayer AG
BeiGene Ltd
Benitec Biopharma Ltd
Bexion Pharmaceuticals LLC
BioDiem Ltd
Biohaven Pharmaceutical Holding Company Ltd
Biomics Biotechnologies Co Ltd
Bionovis SA
BioNTech AG
Biotest AG
Biothera Pharmaceutical Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
CBT Pharmaceuticals Inc
CEL-SCI Corp
Celgene Corp
Cell Medica Ltd
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Celprogen Inc
Centrose LLC
Checkpoint Therapeutics Inc
Corvus Pharmaceuticals Inc
Cristal Therapeutics BV
Critical Outcome Technologies Inc
Curevac AG
Cyclacel Pharmaceuticals Inc
CytImmune Sciences Inc
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Denceptor Therapeutics Ltd
DNJ Pharma Inc
Dynavax Technologies Corp
Eisai Co Ltd
Eleven Biotherapeutics Inc
Eli Lilly and Co
Enzene Biosciences Ltd
Etubics Corp
Eureka Therapeutics Inc
F. Hoffmann-La Roche Ltd
Forty Seven Inc
Fujifilm Corp
G&E Herbal Biotechnology Co Ltd
Galectin Therapeutics Inc
Genelux Corp
Genentech Inc
GeneSegues Inc
Genexine Inc
Genmab A/S
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Gliknik Inc
Glycotope GmbH
Hanmi Pharmaceuticals Co Ltd
Hookipa Biotech AG
Horizon Pharma Plc
Hutchison MediPharma Ltd
Ignyta Inc
Immatics Biotechnologies GmbH
Immunocore Ltd
Immunomedics Inc
Immunovaccine Inc
Immunovative Therapies Ltd
Incyte Corp
Infinity Pharmaceuticals Inc
Innate Pharma SA
Innovation Pharmaceuticals Inc
Inovio Pharmaceuticals Inc
InteRNA Technologies BV
Iovance Biotherapeutics Inc
IRX Therapeutics Inc
ISA Pharmaceuticals BV
ISU ABXIS Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Jounce Therapeutics Inc
Juno Therapeutics Inc
Kite Pharma Inc
Kura Oncology Inc
Laboratoires Pierre Fabre SA
LATITUDE Pharmaceuticals Inc
Loxo Oncology Inc
Lytix Biopharma AS
Mabion SA
MacroGenics Inc
Madrigal Pharmaceuticals Inc.
Marsala Biotech Inc
Mateon Therapeutics Inc
MaxiVAX SA
Meabco A/S
MedImmune LLC
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc
Moderna Therapeutics Inc
Molecular Templates Inc
Moleculin Biotech Inc
NanoCarrier Co Ltd
NantKwest Inc
Natco Pharma Ltd
NeoImmuneTech Inc
Neonc Technologies Inc
Neumedicines Inc
Northwest Biotherapeutics Inc
Novartis AG
Noxopharm Ltd
Oncobiologics Inc
Oncolys BioPharma Inc
Onconova Therapeutics Inc
OncoSec Medical Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Oryx GmbH & Co KG
Otsuka Holdings Co Ltd
PDS Biotechnology Corp
Peregrine Pharmaceuticals Inc
Pfizer Inc
Pharma Mar SA
Plexxikon Inc
PNP Therapeutics Inc
Profectus BioSciences Inc
Provectus Biopharmaceuticals Inc
PsiOxus Therapeutics Ltd
R Pharm
Redx Pharma Plc
Regeneron Pharmaceuticals Inc
Reliance Life Sciences Pvt Ltd
Sareum Holdings Plc
Selecta Biosciences Inc
Shionogi & Co Ltd
Sierra Oncology Inc
Sillajen Biotherapeutics
Sinil Pharmaceutical Co Ltd
Sorrento Therapeutics Inc
Sound Pharmaceuticals Inc
Spherium Biomed SL
Sumitomo Dainippon Pharma Co Ltd
SuviCa Inc
SynCore Biotechnology Co Ltd
Systimmune Inc
Taiwan Liposome Company Ltd
Takara Bio Inc
Takis Srl
Tessa Therapeutics Pte Ltd
Theralase Technologies Inc
Theravectys SA
Tolero Pharmaceuticals Inc
Tosk Inc
Transgene SA
UbiVac LLC
Vaccibody AS
VasGene Therapeutics Inc
Vault Pharma Inc
Vaxeal Holding SA
Vectorite Biomedica Inc
Viracta Therapeutics Inc
Vyriad Inc
Skip to top


Colorectal Cancer - Pipeline Review, H2 2017 US$ 2,500.00 Dec, 2017 · 1962 pages
Prostate Cancer - Pipeline Review, H2 2016 US$ 2,500.00 Dec, 2016 · 1699 pages

Ask Your Question

Head And Neck Cancer - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: